Clinical trial · Interventional
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia
NCT06608342CI-TRIAL-00080951recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia ALL | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous hematopoietic stem cell transplantation combined with CD19-CART | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Autologous hematopoietic stem cell transplantation combined with CD19-CART
- interventionNames
- Biological: Autologous hematopoietic stem cell transplantation combined with CD19-CART
Primary outcomes (1)
- measure
- Relapse rate within 2 years
- timeFrame
- Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation
Secondary outcomes (4)
- measure
- Non-relapse mortality
- timeFrame
- Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation
- measure
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with high-risk acute B-lymphoblastic leukemia * Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared * Eligible for autologous hematopoietic stem cell transplantation * No major organ dysfunction Exclusion Criteria: * Combined with malignant tumors of other organs * With a serious infection that is not under control * Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive * Patients who have had an allergic reaction to the drugs used in this study or similar drugs * Other patients deemed unsuitable for inclusion by the investigators
References
Publications (0)
Data not yet available
No reference posted for this study.